[Treatment osteoporosis and EBM]

Global large scaled clinical trials with new generation of bisphosphonates and raloxifene HCl have been carried out under the spirits of EBM. These pharmaceutical agents have been established as their efficacy of reducing osteoporosis related fragility fractures such as vertebral fractures and non vertebral fractures including hip fractures and applied to clinical use also in Japan. Based on results from clinical trials these agents are listed as first lines in clinical guidelines recently proposed overseas.